AG-1557 hydrochloride

CAS No. ——

AG-1557 hydrochloride ( —— )

Catalog No. M19479 CAS No. ——

AG-1557 is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 49 Get Quote
10MG 78 Get Quote
25MG 155 Get Quote
50MG 286 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AG-1557 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    AG-1557 is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).
  • Description
    AG-1557 is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    hERG|EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    443.66
  • Molecular Formula
    C16H15ClIN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    Cl.COc1cc2ncnc(Nc3cccc(I)c3)c2cc1OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Joshi A. Gadhwal M. and Joshi U.J. Indentification of potential novel EGFR inhibitors using a combination of pharmacophore and docking methods Int. J. Pharm. Pharmaceut. Sci. 7(6) (2015).
molnova catalog
related products
  • ZM 323881 hydrochlor...

    ZZZM 323881 hydrochloride is a potent and selective VEGFR2 inhibitor with IC50 of <2 nM, almost no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2.

  • Befotertinib

    Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.

  • Dacomitinib

    Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively.